Conivaptan and Tezacaftor/ivacaftor and ivacaftor
Determining the interaction of Conivaptan and Tezacaftor/ivacaftor and ivacaftor and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.GENERALLY AVOID: Coadministration with conivaptan may significantly increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4. Conivaptan is a mechanism-based inhibitor of CYP450 3A4. In pharmacokinetic studies with drugs that primarily undergo metabolism by CYP450 3A4 such as midazolam, simvastatin and amlodipine, conivaptan 30 to 40 mg/day has increased systemic exposure (AUC) by 2- to 3-fold. MANAGEMENT: Concomitant use of conivaptan with sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index should generally be avoided. Subsequent treatment with CYP450 3A4 substrates may be initiated no sooner than 1 week after completion of conivaptan treatment. References "Product Information. Vaprisol (conivaptan)." Cumberland Pharmaceuticals Inc, Nashville, TN.
Professional:GENERALLY AVOID: Coadministration with conivaptan may significantly increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4. Conivaptan is a mechanism-based inhibitor of CYP450 3A4. In pharmacokinetic studies with drugs that primarily undergo metabolism by CYP450 3A4 such as midazolam, simvastatin and amlodipine, conivaptan 30 to 40 mg/day has increased systemic exposure (AUC) by 2- to 3-fold.
MANAGEMENT: Concomitant use of conivaptan with sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index should generally be avoided. Subsequent treatment with CYP450 3A4 substrates may be initiated no sooner than 1 week after completion of conivaptan treatment.
- "Product Information. Vaprisol (conivaptan)." Cumberland Pharmaceuticals Inc, Nashville, TN.
Generic Name: ivacaftor / tezacaftor
Brand name: Symdeko, Symdeko 4-Week
Synonyms: Tezacaftor/ivacaftor and ivacaftor (Oral)
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Conivaptan-TGQ 30PSE/3BRM/15DM
- Conivaptan-TGQ 7.5PEH/4BRM/15DM
- Conivaptan-TGT First Aid Antibiotic
- Conivaptan-TGT First Aid Cleansing
- Conivaptan-TH Antibiotic + Pain Relief
- Conivaptan-Thalidomide
- Tezacaftor/ivacaftor and ivacaftor-Conivaptan Hydrochloride
- Tezacaftor/ivacaftor and ivacaftor-Conivaptan Intravenous
- Tezacaftor/ivacaftor and ivacaftor-Conjugated estrogens
- Tezacaftor/ivacaftor and ivacaftor-Conjugated estrogens and bazedoxifene
- Tezacaftor/ivacaftor and ivacaftor-Conjugated estrogens and medroxyprogesterone
- Tezacaftor/ivacaftor and ivacaftor-Conjugated estrogens and medroxyprogesterone Oral